164 related articles for article (PubMed ID: 37097696)
1. Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma.
Sano T; Aizawa R; Ito K; Nakamura K; Ogata T; Takeda M; Hamada A; Matsuoka T; Kono J; Kita Y; Masui K; Goto T; Sawada A; Akamatsu S; Ogawa O; Mizowaki T; Kobayashi T
Anticancer Res; 2023 May; 43(5):2119-2126. PubMed ID: 37097696
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan.
Fujiwara M; Yuasa T; Urasaki T; Komai Y; Fujiwara R; Numao N; Yamamoto S; Yonese J
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1398. PubMed ID: 33934570
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
4. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
Swami U; Haaland B; Kessel A; Nussenzveig R; Maughan BL; Esther J; Sirohi D; Pal SK; Grivas P; Agarwal N
J Urol; 2021 Mar; 205(3):709-717. PubMed ID: 33080152
[TBL] [Abstract][Full Text] [Related]
7. First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
Li JR; Wang SS; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Yang CK
Anticancer Res; 2023 Mar; 43(3):1331-1339. PubMed ID: 36854504
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
[TBL] [Abstract][Full Text] [Related]
9. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
Balar AV; Castellano DE; Grivas P; Vaughn DJ; Powles T; Vuky J; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Necchi A; Petrylak DP; Plimack ER; Xu JZ; Imai K; Moreno BH; Bellmunt J; de Wit R; O'Donnell PH
Ann Oncol; 2023 Mar; 34(3):289-299. PubMed ID: 36494006
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study.
Su R; Chen Z; Hong D; Jiang S; Yuan Y; Cai X; Hu H; Fu C; Huang Z; Wang Z; Zheng B; Huang J; Wang Z; Bao Y; Cai M; Guo J; Chen M; Wei Q; Huang J; Xue W
Cancer Med; 2023 May; 12(9):10587-10596. PubMed ID: 36952461
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
[TBL] [Abstract][Full Text] [Related]
13. Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.
Dang E; Vallée A; Lepage-Seydoux C; Sejean K; Bonan B; Abraham C; Beuzeboc P; Ratta R
Curr Oncol; 2022 Feb; 29(2):945-955. PubMed ID: 35200579
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study.
Minato A; Furubayashi N; Harada M; Negishi T; Sakamoto N; Song Y; Hori Y; Tomoda T; Tamura S; Kuroiwa K; Seki N; Tomisaki I; Harada K; Nakamura M; Fujimoto N
Clin Genitourin Cancer; 2022 Oct; 20(5):499.e1-499.e8. PubMed ID: 35624001
[TBL] [Abstract][Full Text] [Related]
15. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
16. Urothelial carcinoma in the era of immune checkpoint inhibitors.
Khalife N; Chahine C; Kordahi M; Felefly T; Kourie HR; Saleh K
Immunotherapy; 2021 Aug; 13(11):953-964. PubMed ID: 34184561
[TBL] [Abstract][Full Text] [Related]
17. Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
Santoni M; Massari F; Takeshita H; Tapia JC; Dionese M; Pichler R; Rizzo M; Lam ET; Grande E; Kemp R; Molina-Cerrillo J; Calabrò F; Tural D; Küronya Z; Kucharz J; Fiala O; Seront E; Kopp RM; Abahssain H; Kopecky J; Martignetti A; Kanesvaran R; Zakopoulou R; Ansari J; Landmesser J; Mollica V; Porta C; Bellmunt J; Salah S; Santini D
Clin Exp Med; 2023 Dec; 23(8):5413-5422. PubMed ID: 37917218
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.
Narita T; Hatakeyama S; Numakura K; Kobayashi M; Muto Y; Saito M; Narita S; Tanaka T; Noro D; Tokui N; Yoneyama T; Hashimoto Y; Habuchi T; Ohyama C
Int J Urol; 2021 Sep; 28(9):899-905. PubMed ID: 34028105
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study.
Ito K; Kita Y; Yokomizo A; Miki J; Yoshio Y; Matsumoto H; Segawa T; Karashima T; Nishiyama N; Imai K; Suekane S; Nagasawa S; Higashi S; Nishiyama H; Kitamura H; Kobayashi T
Cancer Med; 2023 Feb; 12(3):2325-2332. PubMed ID: 35864744
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for the treatment of bladder cancer.
Sundahl N; Rottey S; De Maeseneer D; Ost P
Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
